Alzheimer's Association launches global trial pairing lifestyle coaching with a GLP-1 drug

PROTECT-Cog, unveiled at AAIC 2026 in London with $100 million in funding, will test whether adding a metabolism-targeting drug to the U.S. POINTER lifestyle program does more to protect thinking skills in at-risk older adults than either approach alone.

The Alzheimer's Association announced on July 13, 2026, at the Alzheimer's Association International Conference (AAIC) in London the launch of PROTECT-Cog, a new $100 million global trial testing whether adding a metabolism-targeting drug, such as a GLP-1 receptor agonist, to a structured lifestyle program does more to protect against cognitive decline than either approach alone, according to the Association's own release.

The trial builds on U.S. POINTER, a two-year, five-site randomized trial that enrolled 2,111 older adults and found a highly structured program of exercise, diet coaching and cognitive training produced somewhat greater improvement in composite cognitive scores than a self-guided version, and on LatAm-FINGERS, which tested a similar program in more than 1,000 older adults across 11 Latin American countries. PROTECT-Cog will compare an intensive "structured" coaching arm against a "structured-lite" version with the same content but fewer contacts, and in a subset of participants will add the metabolism-targeting drug, following everyone for three years with cognitive and health evaluations every six months, the Association said. Maria C. Carrillo, the Association's chief science officer and the study's principal investigator, said "PROTECT-Cog builds directly on what we learned from U.S. POINTER and takes the next critical step in prevention science." Which specific drug will be used, and exactly how participants will be assigned to arms, have not yet been finalized, Medscape Medical News reported.

The case for testing a GLP-1 drug rests on observational data, not a completed randomized trial: large real-world healthcare databases have linked GLP-1 receptor agonist use to a 40 to 70 percent lower relative risk of dementia compared with other diabetes medications, an association the Association's own release says is strongest in people with obesity. That kind of database comparison cannot rule out that healthier or more closely monitored patients were simply more likely to be prescribed the drugs in the first place. A separate randomized trial of oral semaglutide, EVOKE and EVOKE+, enrolled 3,808 people with early Alzheimer's disease and found the drug lowered inflammatory markers but did not slow decline on a standard clinical scale, leading to discontinuation of its extension phase.

Independent researchers describe the new trial as ambitious but unproven. David S. Knopman, a clinical neurologist at the Mayo Clinic who was not involved in designing the study, called PROTECT-Cog "indeed a bold effort" but told Medscape Medical News it faces high recruitment costs and a lengthy follow-up, and said it would need to enroll people with a heavy burden of vascular risk factors to succeed, since he believes the EVOKE trials fell short partly because their participants had little vascular disease.

The Alzheimer's Association has not yet published a target enrollment figure, a list of trial sites, or a clinicaltrials.gov registration number for PROTECT-Cog.